Leukemia | Topics

 
Matthew S. Davids, MD, MMSc, Discusses Rationale for the MAJIC Study of Venetoclax Plus Acalabrutinib in CLL
January 12, 2022

Matthew S. Davids, MD, MMSc, spoke about using venetoclax plus acalabrutinib in the phase 3 MAJIC study for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Acalabrutinib Plus Venetoclax To Be Evaluated in Treatment-Naive CLL/SLL
December 27, 2021

A non inferiority design was presented at ASH 2021 for acalabrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia or small lymphocytic leukemia.

Lindsey Roeker, MD, Discusses Which Data From ASH 2021 Have the Biggest Potential to Impact Care
December 23, 2021

Lindsey Roeker, MD, spoke about data presented at ASH 2021 and what she thought to be most interesting.

High-Frequency, Low-Dose Acalabrutinib Yields Effective Response in CLL/SLL
December 14, 2021

The combination of high-frequency and low-dose acalabrutinib and rituximab demonstrated a 100% overall response rate in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Ibrutinib/Rituximab Combo Demonstrates PFS Superiority Over FCR in Previously Untreated CLL
December 13, 2021

Patients with previously untreated chronic lymphocytic leukemia derived a better progression-free survival benefit from treatment with ibrutinib and rituximab vs fludarabine, cyclophosphamide, and rituximab.

FDA Approves Rituximab Plus Chemo for Select Pediatric Hematologic Malignancies
December 03, 2021

The FDA has approved rituximab plus chemotherapy for previously untreated pediatric CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, and mature B-cell acute leukemia following results from the phase 3 Inter-B-NHL Ritux 2010 study.

How the Study of Leukemias Inspired a Decades-Long Career
November 14, 2021

“I’ve done a lot of work [not only with] clinical trials, but also understanding the disease, the prognostic factors, and the management of adverse effects.”

Racial and Ethnic Diversity in Acute Leukemia Clinical Trials Does Not Appear to Improve With Disparity and Demographic Reporting Requirements
September 07, 2021

After implementing disparity and demographic reporting in acute leukemia clinical trials, investigators did not report an increase in diverse trial participants.

Medical World News® Inside the Practice: CancerNetwork® and Jeffery Auletta, MD, Discuss Mismatched and Unrelated Donor Stem Cell Transplants in Patients With Acute Leukemias and Myelodysplastic Syndrome
July 23, 2021

CancerNetwork® spoke with Jeffery Auletta, MD, about how the National Marrow Donor Program/Be The Match is using research initiatives to expand eligibility for stem cell transplants in for patient with acute leukemias and myelodysplastic syndrome.

Ibrutinib Represents Possible New Treatment Option for Pretreated Hairy Cell Leukemia
July 23, 2021

Results of a phase 2 trial show that ibrutinib was capable of inducing responses in some patients with hairy cell leukemia who were previously treated with standard therapy options in a prior line.